4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Follicular Lymphoma by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 1768 ongoing clinical trials involving Follicular Lymphoma
Of the 1768 trials,447 trials are in Phase III
Furthermore, 438 trials are in Phase I/II

Number of ongoing Clinical Trials (for drugs) involving Follicular Lymphoma by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Follicular Lymphoma, an oncology condition. The largest number of ongoing clinical trials for Follicular Lymphomais conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Follicular Lymphoma-related drug trials.

University of Texas MD Anderson Cancer Center and Celgene Corp: The leading ongoing Follicular Lymphoma related clinical trial sponsors

University of Texas MD Anderson Cancer Center and Celgene Corp are the top sponsors for Follicular Lymphoma-related ongoing clinical trials.

F. Hoffmann-La Roche Ltd, National Cancer Institute US, City of Hope, Mayo Clinic, and Memorial Sloan Kettering Cancer Center are among other notable clinical trial sponsors involved in Follicular Lymphoma. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Follicular Lymphoma

Lisocabtagene maraleucel (Breyanzi), Obinutuzumab (Gazyva, Gazyvaro, Gaziva), and Axicabtageneciloleucel (KTE-C19 / Yescarta) are among the key marketed drugs involving Follicular Lymphoma.

Lisocabtagene maraleucel (Breyanzi) is a CD19-directed genetically modified autologous T cell immunotherapy administered as a defined composition of chimeric antigen receptor (CAR) -positive viable T cells. It functions via Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19 (B Lymphocyte Surface Antigen B4 or Differentiation Antigen CD19 or T Cell Surface Antigen Leu 12 or CD19); Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) Agonist mechanism of action. Lisocabtagene maraleucel is formulated as suspension for intravenous route of administration. Breyanzi is indicated for the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B. Lisocabtagene maraleucel was first approved in 2021 and is marketed in the US and Japan by Juno Therapeutics Inc and Celgene KK.

Obinutuzumab (Gazyva, Gazyvaro, Gaziva) is a glycoengineered, fully humanized IgG1 monoclonal antibody with anti-neoplastic activity. It functions via Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20 mechanism of action. Obinutuzumab is formulated as injectable concentrate solution for intravenous route of administration. Capecitabine was first approved in 2013 and is marketed globally including the US, the UK, Australia, France, Germany and Japan by by several prominent pharma giants including Genentech USA Inc.